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The transduction of T cells to express chimeric T-cell antigen receptor (CAR) is an attractive strategy for adaptive immunotherapy
for cancer, because the CAR can redirect the recognition speciﬁcity of T cells to tumor-associated antigens (TAAs) on the surface
of target cells, thereby avoiding the limitations of HLA restriction. However, there are considerable problems with the clinical
applicationofCAR,mostlyduetoitsxenogeneiccomponents,whichcouldbeimmunogenicinhumans.Moreover,whileextensive
studies on the CARs have been performed, the detailed molecular mechanisms underlying the activation of CAR-grafted T cells
remain unclear. In order to eliminate potential immunogenicity and investigate the molecular basis of the CAR-mediated T-
cell activation, we constructed a novel CAR (CAR57-28ζ) speciﬁc for one of the most important TAAs, epithelial cell adhesion
molecule (EpCAM), using only human-derived genes. We revealed that in Jurkat T cells, lentivirally expressed CAR57-28ζ can
transmit the T-cell-activating signals suﬃcient to induce IL-2 production upon EpCAM stimulation. An immunoﬂuorescent
analysis clearly showed that the CAR57-28ζ induces the formation of signaling clusters containing endogenous CD3ζ at the
CAR/EpCAM interaction interface. These results suggest that this CAR gene may be safely and eﬀectively applied for adaptive
T-cell immunotherapy.
1.Introduction
The chimeric T-cell antigen receptor (CAR) provides a
promising approach for adoptive T-cell immunotherapy for
cancer [1, 2]. Commonly, CARs comprise a single chain
fragment variable (scFv) of an antibody speciﬁc for a tumor-
associated antigen (TAA) coupled via hinge and trans-
membrane regions to several cytoplasmic domains of T-cell
signaling molecules, such as CD3ζ and CD28 [3, 4]. The
CAR-mediated adoptive immunotherapy is thought to be
suitable, especially for cancer cells that have acquired the
ability to escape from immunosurveillance by HLA-down-
regulation and/or a lack of expression of costimulatory mol-
ecules, because the use of scFv as an antigen-binding region
allows CAR-grafted T cells to directly recognize the TAAs on
target tumor cells in a non-HLA-restricted manner. There-
fore, the intrinsic signaling domains of CAR can transmit
multiple stimulatory signals to the T cell. However, the ma-
jorityoftheCARsreportedsofarcontainanscFvmoietythat
originated from murine-derived or “humanized” antibodies
for speciﬁc recognition of TAAs, which might trigger a host
immune response and have inherent risks for the production
of human anti-mouse antibodies (HAMA) [5]. Of note,
extensivestudiesonthetherapeuticapplicationofCARshave
been performed, but the detailed molecular mechanisms
underlying the CAR-mediated activation of the genetically
modiﬁed T cells remain unclear.
We previously reported the establishment of hybridoma
clones that produce a fully human monoclonal antibody
speciﬁc for the epithelial cell adhesion molecule (EpCAM)
[6] using the KMTM mouse, which carries human-de-
rived immunoglobulin genes instead of the endogenous
mouse genes [7]. EpCAM is a transmembrane glycoprotein
expressed by both normal and malignant cells of epithelial2 Journal of Biomedicine and Biotechnology
origin, but that is overexpressed in most human carci-
nomas and is known to be an attractive target TAA for
cancer immunotherapy [8, 9]. Here, in order to remove
the undesired immunogenicity that may arise from CAR-
mediated immunotherapy, we functionally cloned an anti-
EpCAM scFv gene from M13-57, one of the human anti-
EpCAM antibody-producing hybridomas, and a novel CAR
gene speciﬁc for EpCAM was constructed using only human
genes. This CAR gene (referred to hereafter as “CAR57-
28ζ”) was lentivirally expressed in Jurkat T cells, and its
molecular characterization was carried out to investigate
the molecular mechanisms by which CAR leads to T-cell
activation by immunoblotting analyses, assays for cytokine
production, and confocal immunoﬂuorescence microscopy
after stimulation with immobilized EpCAM. We herein
reveal that EpCAM-dependent activation of CAR57-28ζ-
grafted T cells and our discovery that the CAR is able to
deliveractivationsignalsviawild-typeT-cellreceptor(TCR-)
like molecular events, including the formation of signaling
clusters at the antigen-receptor interface.
2.MaterialsandMethods
2.1. cDNA Cloning of Anti-EpCAM scFv. Cloning of the anti-
EpCAM scFv gene was performed using a phage display
technique,asdescribedpreviously[11].TemplatemRNAwas
extractedfromthehybridomacloneM13-57,andthecDNAs
coding for variable regions of the VH and VL genes was PCR
ampliﬁedusing amixtureofhumanV-gene-speciﬁcforward
and reverse primers [12] using the One-Step RT-PCR kit
(Stratagene, La Jolla, CA). An scFv linker DNA that connects
VH to VL was prepared by PCR ampliﬁcation using modiﬁed
RHuJH and RHuVκ primers and the phagemid vector pIT2
containing antiubiquitin scFv as a template [12, 13]. The
VH and VL fragments were assembled into the scFv form by
splice overlap extension (SOE) PCR. The PCR products were
ligated into the Sﬁ Ia n dNot I sites of pIT2. The resulting
plasmid was transformed into Escherichia coli TG-1. Phage
particles displaying anti-EpCAM scFv were prepared using
the KM13 helper phage, and aﬃnity panning was performed
against an EpCAM-coated Maxisorp immunotube (Nunc,
Roskilde,Denmark).Phagebinderswereelutedwithtrypsin-
PBS. The eluted phages were infected into TG-1 cells,
and then they were plated out on 2xTY plates containing
100μg/mL ampicillin. The colonies were picked up, and
a monoclonal phage was prepared from each isolate. The
binders speciﬁc for EpCAM were selected by phage ELISA
using an HRP-conjugated anti-M13 phage antibody (GE
Healthcare, Buckinghamshire, UK) with TMB One Solution
(Promega, Madison, WI). Plasmids were prepared from
selected clones and sequenced.
2.2. Construction and Expression of Anti-EpCAM CAR Genes.
The fully human anti-EpCAM CAR (CAR57-28ζ)g e n ew a s
genetically constructed by exchange of the anti-CEA scFv
region of the CAR45-28ζ gene, which we described previ-
ously [11], for the anti-EpCAM scFv gene that was cloned
here. The CAR57-28ζ gene was temporarily cloned into a
pIRES2-DsRed-Express2 vector (Clontech, Palo Alto, CA) at
the Nhe I site, then a PCR fragment of the CAR with the
IRES2-DsRed Express2 gene was ampliﬁed and subcloned
into a lentiviral expression vector pLVSIN-EF1α (Clontech)
at the Nhe I/Not I sites using an In-Fusion HD cloning kit
(Clontech). The resultant vector was transfected into Lenti-
X 293T cells, and the lentiviral particles were produced from
the cells by using a Lenti-X HT packaging system (Clontech)
according to the manufacturer’s instructions. Lentiviral
stocks were concentrated using Lenti-X concentrator (Clon-
tech),andthetiterwasestimatedwithLenti-XGoStix(Clon-
tech). For infection, nontissue culture 35mm plates were
coated with 20μg/mL Retronectin (Takara Bio Inc., Shiga,
Japan)overnightat4◦C.Thenextday,theplateswerewashed
with D-PBS containing 2% BSA and blocked with the same
buﬀerfor1hrat25◦C.Theplateswerewashedandincubated
with viruses for 4hr at 37◦C. Unbound viral particles were
removed by washing, and Jurkat cells (2.5 × 105 cells) in
RPMI1640mediumsupplementedwith10%fetalcalfserum
(FCS) were plated onto the plates. After 48hr of incubation,
the CAR-transduced cells were collected and inoculated into
anewplate,andthecellswereselectedinmediumcontaining
400μg/mL hygromycin. The cells were analyzed for DsRed
Express2 expression by a ﬂow cytometry analysis, using a
FACS Calibur analyzer (BD Biosciences, San Jose, CA).
For the immunoﬂuorescent analysis, the pBI-ZAP-
AcGFP vector [11] was transfected into CAR57-28ζ-express-
ing Jurkat cells with the GenePORTER 3000 Transfection
Reagent (Genlantis, San Diego, CA).
2.3. IL-2 Secretion Assay. Microtiter plates were coated with
an anti-CD3ε (UCHT1; 500ng/mL; Beckman Coulter, Mi-
ami, FL) or anti-CD28 antibody (CD28.2; 500ng/mL; Beck-
man Coulter) or with EpCAM (20μg/mL). Jurkat cells (1 ×
106 cells/mL) were incubated for 24h at 37◦Ci nc o a t e d
plates. The culture supernatants were analyzed for the secre-
tion of IL-2 using a DIAplex immunoassay kit (Gen-Probe
Inc.,SanDiego,CA)asperthemanufacturer’sspeciﬁcations.
2.4. Western Blotting Analyses. The Jurkat cells were stim-
ulated with immobilized anti-CD3ε alone, anti-CD3ε plus
anti-CD28, or immobilized EpCAM for 15min at 37◦C. The
cells were suspended in RIPA buﬀer (PBS, 1% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS, 2mM EDTA)
at a concentration of 1 × 107 cells/mL, then were incubated
for 1h on ice and then boiled in SDS-PAGE sample buﬀer
with 0.1M dithiothreitol. The samples were separated on 5–
20% acrylamide gradient gels and transferred to polyvinyli-
dene ﬂuoride membranes. The blots were blocked with
StartingBlock T20 blocking buﬀer (SB; Thermoscientiﬁc,
Bremen, Germany), and the membranes were incubated
for 1h with phospho-speciﬁc antibodies (Anti-ACTIVE;
Promega), washed ﬁve times in PBS containing 10% SB,
and protein spots were detected using an HRP-conjugated
secondary antibody. Immunoreactive bands were visualized
using the ECL Prime Western Blotting Detection Reagent
(GEHealthcare)andthenweredevelopedusingtheLAS3000
chemiluminescence system (Fujiﬁlm, Tokyo, Japan).Journal of Biomedicine and Biotechnology 3
2.5. Cell Spreading Assay. A cell spreading assay was per-
formed as described previously, with some modiﬁcations
[11, 14]. Eight-chambered coverslips (Lab-Tek II; Nunc)
were treated with a 0.01% poly-l-lysine solution (Sigma, St.
Louis, MO). The slides were coated overnight at 4◦Cw i t h
anti-CD3ε (10μg/mL) or EpCAM (20μg/mL). Cells (5 ×
105) were seeded onto the bottoms of the chambers
containing phenol red-free RPMI 1640 medium with
10% FCS and 20mM N-2-hydroxyethylpiperazine-N -2-
ethanesulfonic acid for 3min and ﬁxed for 30min at 37◦C
with 8% paraformaldehyde in PBS. The chambers were
washed with PBS containing 10mM glycine and blocked
for 15min in SB at room temperature. The chambers were
incubated for1h at room temperature with a phycoerythrin-
labeled antimyc antibody (Abcam, Cambridge, UK). The
cells were permeabilized for 5min with 0.1% Triton X-
100, rinsed in PBS containing 10% SB, and blocked for
15min in 100% SB. The chambers were incubated for
1h at room temperature and then overnight at 4◦Cw i t h
an anti-CD3ζ antibody (Santa Cruz Biotechnologies,
Santa Cruz, CA) prelabeled with Zenon Alexa Fluor 647
(Invitrogen, Carlsbad, CA). The chambers were washed with
10% SB and reﬁxed for 15min with 4% paraformaldehyde,
then washed in PBS containing 10mM glycine. Fluorescent
images were acquired on a LSM710 confocal system (Carl
Zeiss, Jena, Germany).
3. Results andDiscussion
Because hybridoma cells often express more than one of the
VH/VL genes due to the presence of fusion partners [15],
the functional screening of VH/VL genes is an essential step
for cloning the V-gene encoding a monoclonal antibody.
We employed a phage display technique in order to directly
clone the gene encoding the functional anti-EpCAM scFv.
The cDNAs of VH and VL were ampliﬁed from reverse-
transcribed mRNA of the M13-45 hybridoma with mixed
primers speciﬁc for the V-gene leader and constant regions.
The ampliﬁed V-gene fragments were assembled into the
scFv form with a ﬂexible linker by SOE-PCR to display
the scFv protein on the phage. The scFv genes were lig-
ated into a pIT2 phagemid vector and used to transform
E. coli TG-1 for preparation of the scFv-displaying phages.
Speciﬁc binders were selected by phage ELISA after two
rounds of phage panning on immobilized EpCAM. Some
clones clearly showed speciﬁc binding against EpCAM but
negligible binding to BSA (Figure 1), thus indicating that
the anti-EpCAM scFv harboring phages were successfully
enriched. The DNA sequences of positive scFv clones were
determined, and it was found that they had essentially the
same sequence (Figure 2).
Using the cloned scFv gene, a gene coding an EpCAM-
speciﬁc CAR was constructed. This CAR57-28ζ gene consists
of a CD8 leader sequence, scFv, the transmembrane and
cytoplasmic domains of CD28, and the cytoplasmic domain
of CD3ζ. All of the genes used for the construction were



















































































Figure 1: The screening of phage clones displaying anti-EpCAM
scFv by monoclonal phage ELISA. The binding of phages displaying
anti-EpCAMscFvtoimmobilizedEpCAM(whitebar)orBSA(gray
bar) was detected by an HRP-labeled anti-M13 antibody.
and Methods, the CAR57-28ζ, together with the gene encod-
ing IRES-DsRed Express2, was inserted into the lentiviral
expression vector pLVSIN-EF1α (Figure 2). This expression
construct was then transduced into the packaging cell line,
Lenti-X 293T, and lentiviral particles produced by 293T cells
were used to transduce human T-cell leukemia Jurkat cells.
After hygromycin selection of the transductant, the expres-
sion of the CAR57-28ζ protein was evaluated by a Western
blotting analysis. The cell lysates from mock-transduced
and transduced Jurkat cells were probed with an anti-CD3ζ
antibody, which is capable of recognizing both the CD3ζ
region of the CAR and the endogenous CD3ζ. As shown in
Figure 3, a band of ca. 56kDa consistent with the predicted
size of CAR57-28ζ was detected only in lysates from CAR-
transduced cells, indicating successful expression. The low
ﬂuorescence intensity in the transduced cells observed in
FACS analysis might be due to the poor IRES function.
TCR activation triggers various downstream signaling
events that involve the phosphorylation of cellular proteins
in T cells [16, 17]. To investigate the early steps of T-cell
signal transduction by the CAR, the activation status of the
known signaling components downstream of the TCR was
analyzed by immunoblotting with phosphospeciﬁc antibod-
ies. When wild-type and CAR-expressing Jurkat cells were
activated with stimulating antibodies (anti-CD3ε/CD28), all
signaling molecules tested were phosphorylated in both cells
(Figure 4). Notably, stimulation with immobilized EpCAM
also induced the phosphorylation of ERK, JNK, and p38 in
CAR-expressing cells, but not in wild-type cells (Figure 4).
These observations clearly demonstrated that CAR57-28ζ
was functionally expressed and able to transmit the T-cell
activation signals in an EpCAM-dependent manner.
The CAR-mediated T-cell activation was further inves-
tigated by a cytokine secretion assay. No IL-2 secretion was



























Figure 2: Schematic representations of CAR57-28ζ. The nucoleotide and aminoacid sequences of anti-EpCAM scFv from the M13-57
hybridoma were analyzed using the IMGT/V-QUEST and IMGT/JunctionAnalysis online tools (http://www.imgt.org/), and each comple-
mentarity-determining region (CDR) of the cloned scFv gene was determined according to Chothia’s deﬁnition [10]. VH, variable region of
































Figure 3: The results of the analysis of CAR57-28ζ protein expression. CAR57-28ζ-grafted Jurkat cells after hygromycin selection were
analyzed by ﬂow cytometry (a). Lysates were prepared from wild-type and CAR-expressing Jurkat cells, and immunoreactive bands were

























Figure 4: The phosphorylation status of the signaling proteins in
CAR-expressing Jurkat cells. Cells were activated for 15min with
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Figure 5: IL-2 secretion from CAR-expressing Jurkat cells. The
concentration of IL-2 in the cell supernatant was measured 24h
after stimulation with an anti-CD3 antibody, anti-CD3 plus anti-
CD28 antibodies, or EpCAM.
cells stimulated with EpCAM, nor in those treated with
anti-CD3ε alone (Figure 5). In contrast, EpCAM stimulation
clearly induced the production of IL-2 in CAR-expressing
Jurkat cells similar to when the cells were stimulated with
both anti-CD3ε/CD28 (Figure 5), thus indicating that the
CD28 cytoplasmic domain in CAR57-28ζ could deliver the
costimulatory signal and activate the T-cell signaling path-
way(s) required for the production of IL-2 by stimulation
with EpCAM.
In order to gain insight into the molecular mechanisms
underlying CAR-mediated T-cell activation, we performed
a cell spreading assay. If T cells are dropped onto a surface
coated with stimulatory molecules, this results in receptor
clustering and the recruitment of signaling proteins to the
pointsofcontactwiththestimulatorysurface[14,18].Inour
assay system, the formation of immunoreceptor tyrosine-
based activation motif (ITAM-) mediated signaling clus-
ters was visualized by utilizing the AcGFP-tagged ZAP-70.
ZAP-70 is a predominant T-cell protein tyrosine kinase
containing tandem SH2 domains, which are engaged by
doubly phosphorylated ITAMs of CD3ζ [17, 19]. As shown
in Figure 6, when Jurkat cells expressing ZAP-AcGFP alone
were introduced onto the anti-CD3ε-coated bottom sections
of the chambers, the endogenous TCRs detected with anti-
CD3ζ were observed in ZAP-containing signaling clusters.
As expected, no such cells adhered to the coverslips when
EpCAM was used as a coating protein (data not shown). On
the other hand, the CAR57-28ζ-expressing cells remained
on the EpCAM-coated surface even after washing, and clear
colocalization of CAR57-28ζ and ZAP-70 was observed
(Figure 6).TheseresultsrevealedthatCAR57-28ζ caninduce
the antigen-dependent formation of the signaling clusters
at the antigen/antibody (namely, EpCAM/CAR) interaction
interface. It should be noted that the immunoﬂuorescent
signals detected with the anti-CD3ζ antibody indicate the
localization of endogenous TCRs, as well as that of CAR57-
28ζ, implying that a cross-activation of endogenous TCRs
was induced by CAR and EpCAM.
4. Conclusion
In this study, we constructed CAR57-28ζ, a novel CAR gene
speciﬁc for EpCAM, and found that the CAR gene can
be functionally expressed in T cells. Because CAR57-28ζ
consists of only gene products of human origin, it is likely
to be less immunogenic than some alternative formats (e.g.,
mouse or humanized scFv) upon application for adoptive T-
cell immunotherapy. We also demonstrated that the CAR-
expressing T cells are activated through wild-type TCR-like
molecular events mediated by the interaction of the CAR
with its corresponding antigen, EpCAM. With regard to
the endogenous TCRs, the lifespan and dynamics of the
signaling clusters are one of the critical determinants of
the activation and fate of T cells [20, 21]. Therefore, it
would be important to quantitatively examine how long
the CAR-containing clusters are sustained, and where the
clusters migrate. To answer these questions, real-time live
cell imaging of CAR-expressing cells might be helpful.
Since, as compared with T-cell-stimulating antibodies, T-
cell activation achieved by CAR57-28ζ was not so suﬃcient,
further improvement of molecular design of CAR (e.g.,
the addition of costimulatory domain from other signaling
proteins or the optimization of the signal sequence for
eﬃcient membrane sorting) is inevitable to accomplish the
clinically eﬀective CAR-mediated adaptive immunotherapy
[1, 22]. Further studies are currently underway to transduce
the CAR gene into human peripheral T lymphocytes and to6 Journal of Biomedicine and Biotechnology
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plated on stimulatory coverslips coated with anti-CD3ε, then ﬁxed and stained with ﬂuorescently-labeled anti-CD3ζ.C o n f o c a li m a g e sa tt h e
interface between the attached cells and the stimulatory surface were collected (a). Jurkat cells coexpressing ZAP-70-AcGFP and CAR57-28ζ
wereplatedontoEpCAM-coatedcoverslipsandstainedwithanti-mycandAlexa-labeledanti-CD3ζ antibodies,asdescribedinSection 2(b).
determine the cytotoxic activity of the CAR-grafted T cells
against EpCAM-positive tumor cells.
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